China’s HUYA Biotech, Solvay Of U.S. To Partner In Drug Development

China's HUYA Bioscience International has signed a deal with U.S.-based Solvay Pharmaceuticals to share HUYA's portfolio of compounds. HUYA has several compounds for targeting cardiovascular diseases and a partnership with Solvay is seen as one way to speed development and get the drugs to market. Many of the compounds already are in advanced stages of development in China. The Chinese biotech counts two headquarters, one in Shanghai and the other in San Diego. (Click here for more

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip